Skip to main content
SpringerLink
Log in

Histone deacetylase inhibitor BML-210 induces growth inhibition and apoptosis and regulates HDAC and DAPC complex expression levels in cervical cancer cells

  • Published:
Molecular Biology Reports Aims and scope Submit manuscript

Abstract

Histone deacetylase inhibitors (HDACIs) represent a new class of targeted anti-cancer agents and different other diseases, like muscular disorders. A number of studies have shown that extracellular signal-activated kinases can target chromatin-modifying complexes directly and regulate their function. The molecular connection between the dystrophin-associated protein complex (DAPC) and chromatin has been described, by showing that NO signaling regulates histone deacetylase (HDAC) activity and influences gene expression in different cell types. In present study, we investigated HDACs changes in HeLa cells undergoing growth inhibition and apoptosis, caused by HDACI BML-210 and retinoic acid (ATRA). Cell cycle analysis indicated that HeLa cell treatment with 20 and 30 μM concentration of BML-210 increased the proportion of cells in G0/G1 phase, and caused accumulation in subG1, indicating that the cells are undergoing apoptosis. We determined down-regulation of HDAC 1–5 and 7 after treatment with BML-210. Also, we demonstrated expression of different isoforms of alpha-dystrobrevin (α-DB) and other components of DAPC such as syntrophin, dystrophin, beta-dystrobrevin (β-DB) and NOS in HeLa cells after treatments. We determined changes in protein expression level of dystrophin, NOS1, α- and β-DB and in subcellular localization of α-DB after treatments with BML-210 and ATRA. In conclusion, these results suggest that HDACI BML-210 can inhibit cell growth and induce apoptosis in cervical cancer cells, what correlates with down-regulation of HDAC class I and II and changes in the DAPC expression levels. This can be important for identifying target proteins in DAPC signaling to HDACs, as a target of pharmacological intervention for treatment of muscular dystrophies and other diseases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Bruserud O, Stapnes C, Tronstad KJ, Ryningen A, Anensen N, Gjertsen BT (2006) Protein lysine acetylation in normal and leukaemic haematopoiesis: HDACs as possible therapeutic targets in adult AML. Expert Opin Ther Targets 10:51–68

    Article  PubMed  CAS  Google Scholar 

  2. Demary K, Wong L, Spanjaard RA (2001) Effects of retinoic acid and sodium butyrate on gene expression, histone acetylation and inhibition of proliferation of melanoma cells. Cancer Lett 163:103–107

    Article  PubMed  CAS  Google Scholar 

  3. Milde-Langosch KA, Bamberger M, Methner C, Rieck G, Loning T (2000) Expression of cell cycle-regulatory proteins rb, p16/MTS1, p27/KIP1, p21/WAF1, cyclin D1 and cyclin E in breast cancer: correlations with expression of activating protein-1 family members. Int J Cancer 87:468–472

    Article  PubMed  CAS  Google Scholar 

  4. Yoshida M, Kijima M, Akita M, Beppu T (1990) Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 265:17174–17179

    PubMed  CAS  Google Scholar 

  5. Zolota V, Sirinian C, Melachrinou M, Symeonidis A, Bonikos DS (2007) Expression of the regulatory cell cycle proteins p21, p27, p14, p16, p53, mdm2, and cyclin E in bone marrow biopsies with acute myeloid leukemia, correlation with patients’ survival. Pathol Res Pract 203:199–207

    Article  PubMed  CAS  Google Scholar 

  6. Koshizuka K, Kubota T, Said J, Koike M, Binderup L, Uskokovic M, Koeffler HP (1999) Combination therapy of a vitamin D3 analog and all-trans-retinoic acid: effect on human breast cancer in nude mice. Anticancer Res 19:519–524

    PubMed  CAS  Google Scholar 

  7. Whetstine JR, Ceron J, Ladd B, Dufourcq P, Reinke V, Shi Y (2005) Regulation of tissue-specific and extracellular matrix-related genes by a class I histone deacetylase. Mol Cell 18:483–490

    Article  PubMed  CAS  Google Scholar 

  8. Joseph J, Mudduluru G, Antony S, Vashistha S, Ajitkumar P, Somasundaram K (2004) Expression profiling of sodium butyrate (NaB)-treated cells: identification of regulation of genes related to cytokine signaling and cancer metastasis by NaB. Oncogene 23:6304–6315

    Article  PubMed  CAS  Google Scholar 

  9. Deroanne CF, Bonjean K, Servotte S, Devy L, Colige A, Clausse N, Blacher S, Verdin E, Foidart JM, Nusgens BV, Castronovo V (2002) Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene 21:427–436

    Article  PubMed  CAS  Google Scholar 

  10. Kuwajima A, Iwashita J, Murata J, Abe T (2007) The histone deacetylase inhibitor butyrate inhibits melanoma cell invasion of Matrigel. Anticancer Res 27:4163–4169

    PubMed  CAS  Google Scholar 

  11. Spira AI, Carducci MA (2003) Differentiation therapy. Curr Opin Pharmacol 3:338–343

    Article  PubMed  CAS  Google Scholar 

  12. Ortiz MA, Bayon Y, Lopez-Hernandez FJ, Piedrafita FJ (2002) Retinoids in combination therapies for the treatment of cancer: mechanisms and perspectives. Drug Resist Updates 5:162–175

    Article  CAS  Google Scholar 

  13. Savickiene J, Borutinskaite VV, Treigyte G, Magnusson KE, Navakauskiene R (2006) The novel histone deacetylase inhibitor BML-210 exerts growth inhibitory, proapoptotic and differentiation stimulating effects in the human leukemia cell lines. Eur J Pharmacol 549:9–18

    Article  PubMed  CAS  Google Scholar 

  14. Yoo CB, Jones PA (2006) Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 5:37–50

    Article  PubMed  CAS  Google Scholar 

  15. Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK, Benz CC (2005) Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol 45:495–528

    Article  PubMed  CAS  Google Scholar 

  16. Glozak MA, Sengupta N, Zhang X, Seto E (2005) Acetylation and deacetylation of non-histone proteins. Gene 363:15–23

    Article  PubMed  CAS  Google Scholar 

  17. Weichert W (2009) HDAC expression and clinical prognosis in human malignancies. Cancer Lett 280:168–176

    Article  PubMed  CAS  Google Scholar 

  18. Rando TA (2001) The dystrophin-glycoprotein complex, cellular signaling, and the regulation of cell survival in the muscular dystrophies. Muscle Nerve 24:1575–1594

    Article  PubMed  CAS  Google Scholar 

  19. Kulyte A, Navakauskiene R, Treigyte G, Gineitis A, Bergman T, Magnusson KE (2002) Characterization of human alpha-dystrobrevin isoforms in HL-60 human promyelocytic leukemia cells undergoing granulocytic differentiation. Mol Biol Cell 13:4195–4205

    Article  PubMed  CAS  Google Scholar 

  20. Colussi C, Mozzetta C, Gurtner A, Illi B, Rosati J, Straino S, Ragone G, Pescatori M, Zaccagnini G, Antonini A, Minetti G, Martelli F, Piaggio G, Gallinari P, Steinkuhler C, Clementi E, Dell’Aversana C, Altucci L, Mai A, Capogrossi MC, Puri PL, Gaetano C (2008) HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment. Proc Natl Acad Sci USA 105:19183–19187

    Article  PubMed  CAS  Google Scholar 

  21. Consalvi S, Saccone V, Giordani L, Minetti G, Mozzetta C, Puri PL (2011) Histone deacetylase inhibitors in the treatment of muscular dystrophies: epigenetic drugs for genetic diseases. Mol Med 17:457–465

    Article  PubMed  CAS  Google Scholar 

  22. Grady RM, Grange RW, Lau KS, Maimone MM, Nichol MC, Stull JT, Sanes JR (1999) Role for α-dystrobrevin in the pathogenesis of dystrophin-dependent muscular dystrophies. Nat Cell Biol 1:215–220

    Article  PubMed  CAS  Google Scholar 

  23. Nawrotzki R, Loh NY, Ruegg MA, Davies KE, Blake DJ (1998) Characterisation of alpha-dystrobrevin in muscle. J Cell Sci 111:2595–2605

    PubMed  CAS  Google Scholar 

  24. Sadoulet-Puccio HM, Khurana TS, Cohen JB, Kunkel LM (1996) Cloning and characterization of the human homologue of a dystrophin related phosphoprotein found at the Torpedo electric organ post-synaptic membrane. Hum Mol Genet 5:489–496

    Article  PubMed  CAS  Google Scholar 

  25. Fuentes-Mera L, Rodríguez-Munoz R, Gonzalez-Ramírez R, García-Sierra F, Gonzalez E, Mornet D, Cisneros B (2006) Characterization of a novel Dp71 dystrophin-associated protein complex (DAPC) present in the nucleus of HeLa cells: members of the nuclear DAPC associate with the nuclear matrix. Exp Cell Res 312:3023–3035

    Article  PubMed  CAS  Google Scholar 

  26. Yoshida M, Hama H, Ishikawa-Sakurai M, Imamura M, Mizuno Y, Araishi K, Wakabayashi-Takai E, Noguchi S, Sasaoka T, Ozawa E (2000) Biochemical evidence for association of dystrobrevin with the sarcoglycan–sarcospan complex as a basis for understanding sarcoglycanopathy. Hum Mol Genet 9:1033–1040

    Article  PubMed  CAS  Google Scholar 

  27. Xiao JX, Huang GQ, Zhang SH (2007) Soyasaponins inhibit the proliferation of HeLa cells by inducing apoptosis. Exp Toxicol Pathol 59:35–42

    Article  PubMed  CAS  Google Scholar 

  28. Wink DA, Mitchell JB (1998) Chemical biology of nitric oxide: insights into regulatory, cytotoxic, and cytoprotective mechanisms of nitric oxide. Free Radic Biol Med 25:434–456

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This research was supported by the Swedish Institute (Visby Program No. 00879/2009–2010), the Swedish Research Council, Lithuanian State Science and Studies Foundation (No. V-12/2009) and EU Marie Curie Programme Fellowship for V.V. Borutinskaite.

Author information

Authors and Affiliations

  1. Department of Molecular Cell Biology, Institute of Biochemistry, Vilnius University, 08662, Vilnius, Lithuania

    Veronika V. Borutinskaite & Ruta Navakauskiene

  2. Division of Medical Microbiology, Department of Molecular and Clinical Medicine, Linköping University, 581 85, Linköping, Sweden

    Karl-Eric Magnusson

Authors
  1. Veronika V. Borutinskaite
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Karl-Eric Magnusson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ruta Navakauskiene
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Veronika V. Borutinskaite.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Borutinskaite, V.V., Magnusson, KE. & Navakauskiene, R. Histone deacetylase inhibitor BML-210 induces growth inhibition and apoptosis and regulates HDAC and DAPC complex expression levels in cervical cancer cells. Mol Biol Rep 39, 10179–10186 (2012). https://doi.org/10.1007/s11033-012-1892-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11033-012-1892-5

Keywords

Search

Navigation